Monitoring responses to antiangiogenic agents using noninvasive imaging tests

Cancer Journal from Scientific American

Volumn 5, Issue 5, 1999, Pages 252-256

  Libutti, Steven K ^a   Choyke, Peter ^b   Carrasquillo, Jorge A ^c   Bacharach, Stephen ^c   Neumann, Ronald D ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Department of Radiology ^*  (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

CANCER THERAPY; DIAGNOSTIC IMAGING; DOSE RESPONSE; HUMAN; IMAGE PROCESSING; MITOSIS INHIBITION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; TUMOR BLOOD FLOW; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN; DIAGNOSTIC IMAGING; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032845684     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Gupta NC, Rogers JS, Rai A et al. Tumor FDG uptake as a prognostic marker of treatment response and patient outcome in lung cancer [abstract]. J Nucl Med 1999;40:136.
2. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995;36: 109-118.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
4. Vile R. Less blood means more sanguinity. Cancer Ther 1995;5: 10-13.
5. Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer 1995;31A-1101-1104.
6. Cao Y, O'Reilly MS, Marshall B et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. Clin Invest 1998; 101:1055-1063.
7. Kohn EC, Figg WD, Sarosy GA et al. Phase 1 trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. Clin Oncol 1997;15:1985-1993.
8. Eskey CJ, Wolmark N, McDowell CL et al. Residence time distributions of various tracers in tumors - implications for drug-delivery and blood-flow measurement. J Natl Cancer Inst 1994;86: 293-299.
9. Hattori H, Miyoshi T, Okada J et al. Tumor blood-flow measured using dynamic computed-tomography. Invest Radiol 1994; 29:873-876.
10. Hering ER, Blekkenhorst GH, Jones DT. Tumor blood-flow measurements using coincidence counting on patients treated with neutrons. Int J Radiat Oncol Biol Phys 1995:32:129-135.
11. Schelbert HR. Blood flow and metabolism by PET. Cardiol Clin 1994;12:303-315.
12. Brudin LH, Rhodes CG, Valind SO et al. Regional structure-function correlations in chronic obstructive lung disease measured with positron emission tomography. Thorax 1992;47: 914-921.
13. 11CO PET with 99Tcm SPECT. Nucl Med Commun 1994;15: 283-288.
14. Leenders KL. PET: blood-flow and oxygen-consumption in brain-tumors. J Neurooncol 1994;22:269-273.
15. Mineura K, Sasajima T, Itoh Y et al. Blood-flow and metabolism of central neurocytoma: a positron emission tomography study. Cancer 1995;76:1224-1232.
16. Sagar SM, Klassen GA, Barclay KD et al. Tumor blood-flow: measurement and manipulation for therapeutic gain. Cancer Treat Rev 1993;19:299-349.
17. Tomura N, Kato T, Kanno I et al. Increased blood-flow in human brain-tumor after administration of angiotensin-II: demonstration by PET. Comput Med Imaging Graph 1993;17:443-449.
18. Kahn D, Weiner GJ, Hichwa RD. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood. 1994;83: 958-963.
19. Mankoff DA, Dunnwald LK, Gralow JR et al. Changes in blood flow and metabolism in locally advance breast cancer in response to presurgical chemotherapy. J Nucl Med 1999;40:137.
20. Conti PS, Lilien DL, Hawley K et al. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996;23:717-735.
21. DiChiro G. Positron emission tomography using [18F]flurodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-371.
22. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-511.
23. Ito K, Kato T, Tadokoro M. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182: 549-552.
24. van Dijke CF, Brasch RC, Roberts TP et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MRI image characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-818.
25. Hulka CA, Edmister WB, Smith BL et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205: 837-842.
26. Stomper PC, Winston JS, Herman S et al. Angiogenesis and dynamic MRI imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 1997;45:39-46.
27. Buadu LD, Murakami J, Murayama S et al. Breast lesions: correlation of contrast medium enhancement patterns on MRI images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-649.
28. Buckley DL, Drew PJ, Mussurakis S et al. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997;7:461-464.
29. Buadu LD, Murakami J, Murayama S et al. Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. J Comput Assist Tomogr 1997;21:421-430.
30. Hawighorst H, Knapstein PG, Weikel W et al. Angiogenesis of uterine cervical carcinoma characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997; 57:4777-4786.
31. Pearlman JD, Hibberd MG, Chuang ML et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1995;1:1085-1089.
32. Brasch R, Pham C, Shames D et al. Assessing tumor angiogenesis using macromolecular MRI imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
33. Fatigante L, Ducci F, Cartei F et al. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. Int J Radiat Oncol Biol Phys 1997;37:499-504.
34. Griffiths JR, Taylor NJ, Howe FA et al. The response of human tumors to carbogen breathing monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997; 39:697-701.
35. Robinson SP, Howe FA, Rodrigues LM et al. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol 1998;8:197-207.
36. Robinson SP, Howe FA, Griffiths JR. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1995;33:855-859.
37. Al-Hallaq HA, River JN, Zamora M et al. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;41:151-159.